Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
about
Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy.Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particlesCharacteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunityPre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsBinding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58.Papillomavirus capsid proteins mutually impact structureRelationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® VaccineNaturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccineThe U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron MicroscopyDetection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirionsThe papillomavirus major capsid protein L1.Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs.Perspectives for the development of human papillomavirus vaccines and immunotherapy.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands.Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization.High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
P2860
Q30252022-3B8AB7C2-02A0-4CDE-89FA-FBA7B8C3CDE4Q34033805-443BD5E4-B1A0-4F69-8B66-095C9E25486CQ34256293-06E203FC-2B1C-4E16-ADF3-FB4F46E48F32Q34259805-52A2D01F-9353-4FE7-A284-D257DAF5E655Q34352416-F68A9526-6E40-4074-8F0F-CD282896145BQ34492140-0D918809-EDB5-437F-AF56-74FA13A50BB3Q34641651-1454D26A-017A-4884-91EF-3C35A08097DFQ34699403-B6030D65-C0D8-4B6C-AACE-1A839BB88C90Q35818648-CA308B3D-7B5B-443E-AEFC-CD4EA2AD7B9FQ35861286-C1E466FB-4214-487B-9816-824F46554457Q35947703-709052A5-92C3-42F2-8CD8-2236F888D2DBQ36017795-50D6A65E-E03C-40CF-B0FF-3D7553E47C57Q36281141-C77DF933-3791-4D9F-AEB8-2BA7BB601D60Q36422554-01CAF819-B472-4F63-A283-3FBCE3168ABBQ37198519-C1E8F317-1B6B-4CA3-8B89-4CD03E923E9AQ37640226-523E11EB-B1A3-41E9-BC68-AA90FAFF0E16Q37658876-27615BD7-0D18-4233-84B0-A971F4438CD7Q37671423-4C3603FA-1D84-49BD-97C2-7F81E59702D0Q40018417-2131157E-CFEF-431A-A465-1C2B5966A824Q41605239-458C1E87-E4CE-4275-BF5F-08D1C7DB5354Q47136931-6F20F107-FC39-451C-B6AA-EEF1359CCD73Q47143249-CE7FFA34-6672-48F7-9A97-B62096F347DE
P2860
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Binding and neutralization eff ...... d of infectious HPV particles.
@ast
Binding and neutralization eff ...... d of infectious HPV particles.
@en
type
label
Binding and neutralization eff ...... d of infectious HPV particles.
@ast
Binding and neutralization eff ...... d of infectious HPV particles.
@en
prefLabel
Binding and neutralization eff ...... d of infectious HPV particles.
@ast
Binding and neutralization eff ...... d of infectious HPV particles.
@en
P2093
P2860
P1433
P1476
Binding and neutralization eff ...... d of infectious HPV particles.
@en
P2093
Christin M Spatz
Cynthia A Reed
Neil D Christensen
Timothy D Culp
P2860
P304
P356
10.1016/J.VIROL.2006.12.002
P407
P577
2007-01-12T00:00:00Z